Kaluga pharmaceutical cluster produces a full line of modern Novo Nordisk insulins. The Danish company, one of the leaders in the world market of insulin, began to localize its production facilities with the stage of packaging; recently the production of finished dosage form of insulin cartridges and assembly of pre-filled syringe pens were launched, that is, a full production cycle was introduced. What does this mean for company? What will Russian patients get? This was told by Mike Dustar, the Executive Vice President of Novo Nordisk A/S, to RG.
A full cycle plant for the production of insulin was officially launched in Grabtsevo Industrial Park in Kaluga on September 19. The ceremony was attended by the Governor of the Kaluga Region Anatoly Artamonov, Ambassador of the Kingdom of Denmark to the Russian Federation Karsten Sondergaard, Executive Vice President of Novo Nordisk Mike Dustdaar, representatives of Federal and regional agencies and public organizations.
Novo Nordisk will launch production of insulin injection pens – FlexPen at their plant in the Grabtsevo Industrial Park in Kaluga. The Ministry of Industry and Trade of the Russian Federation issued a license to the company for production of insulin finished dosage forms, as reported today by the Company’s press service.
On June 16, an agreement of intent was signed at the 20-th Saint Petersburg International Economic Forum between Novo Nordisk and the government of the Kaluga Region to implement an investment project in the territory of the Kaluga Region The agreement involves the design and construction of a new workshop for the assembly of prefilled FlexPen® pen injectors at the company’s plant in the Kaluga Region. “Today we made another step in our consistent investment policy, which Novo Nordisk sticks to in the Russian market strategic for the company”, said Lars Rebien Sorensen, President and CEO of Novo Nordisk A/S.
Today, Novo Nordisk opens a new manufacturing facility in Russia for formulation and filling of modern insulin for the treatment of diabetes. The production will cover both Penfill® cartridges and FlexPen® prefilled insulin injection pens for the Russian market. The new facility will be operating in accordance with current Good Manufacturing Practices (GMP), and is located in Technopark Grabtsevo in the Kaluga region of Russia. “The manufacturing facility in Kaluga is a sign of our long-term commitment to people with diabetes in Russia, where close to 10 million people have the disease according to local studies. With our investment in local manufacturing, we ensure availability of highquality modern insulins to the people with diabetes in Russia who rely on our products every day,” said Lars Rebien Sørensen, CEO of Novo Nordisk. This is the first and only greenfield facility for the manufacturing of modern insulin in Russia. Environmental targets for CO² emission, water consumption and use of energy have been established. With the construction of the new facility, Novo Nordisk has so far created around 150 new jobs. “The opening of Novo Nordisk manufacturing facility in Kaluga is a sign of confidence in our region, as well as an important stage in the formation of a pharmaceutical cluster in Kaluga. I am convinced that the new facility will have a significant impact on improving the quality of life for people with diabetes in Kaluga as well as in the rest of Russia,” said Kaluga Region Governor, Anatoly Artamonov. Novo Nordisk also has production sites in Denmark, Brazil, China, France and the US.
Novo Nordisk A/S (NOVOB), the world’s biggest insulin maker, is moving forward with investments in Russia.
Novo is building a plant in Russia and considers its investment there necessary “in the long haul,” Jakob Riis, the Bagsvaerd, Denmark-based company’s head of marketing, medical affairs and stakeholder engagement, said in an interview yesterday.
“Russia is not a mess,” said Riis, speaking in Davos, Switzerland, where he’s attending the World Economic Forum’s annual meeting for the first time. “We want to continue to run good business” in the country, and the new production facility will open soon, he said.
“My personal view is that this will somehow, at some point, quiet down and somehow the economy is going to develop again,” Riis said. “By sheer demographics and resources, it’s going to be an interesting market.”